Zunera Tariq, Jake P Tinsley, Dana Carpenter, Janet K Snell-Bergeon, Viral N Shah
{"title":"Hypophosphatasia and Type 1 Diabetes: A Pilot Study and Review of Literature.","authors":"Zunera Tariq, Jake P Tinsley, Dana Carpenter, Janet K Snell-Bergeon, Viral N Shah","doi":"10.1007/s11914-025-00938-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Hypophosphatasia (HPP) and type 1 diabetes (T1D) are both associated with low bone turnover and increased fracture risk. In this review, our objectives were to (a) discuss results of our pilot study aimed to evaluate prevalence and clinical and radiological characteristics of HPP in adults with T1D and (b) to review literature on the use of electronic medical records (EMR) for HPP case findings.</p><p><strong>Recent findings: </strong>In our pilot study, 18 individuals had persistent low alkaline phosphatase levels (ALP) [18/1723, 1.05%]. Among 10 participants who completed the study with potential HPP and T1D, three had a pathogenic ALPL mutation (0.16% prevalence), and six had elevated serum vitamin B6. No significant differences were found in DXA-based bone density, QCT-based bone density, or Finite element-estimated bone strength between the potential HPP group, T1D adults, and controls. We did not find any study that evaluated persistent low ALP levels or potential HPP in patients with diabetes (either type 1 or type 2 diabetes). The literature reported higher prevalence of low ALP levels when electronic medical records were searched (~ 1-3%). However, prevalence of suspected HPP based on persistent low ALP levels and/or clinical signs and symptoms was around 0.5% or lower depending on sample size, methods and geographical locations. Our study suggests that EMR-based screening for HPP is feasible and may identify previously undiagnosed cases of HPP. Prevalence of potential HPP in T1D is around 1% and genetically confirmed HPP is 0.16% which is similar to reported prevalence of HPP in selected population without diabetes. Skeletal imaging and clinical presentations are not sufficient for identifying potential HPP in individuals with T1D. Given the increased fracture risk and low bone turnover typically seen in T1D, we propose that an EMR-based screening strategy could be a more effective approach for diagnosing HPP in T1D population.</p>","PeriodicalId":48750,"journal":{"name":"Current Osteoporosis Reports","volume":"23 1","pages":"42"},"PeriodicalIF":5.3000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Osteoporosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11914-025-00938-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose of review: Hypophosphatasia (HPP) and type 1 diabetes (T1D) are both associated with low bone turnover and increased fracture risk. In this review, our objectives were to (a) discuss results of our pilot study aimed to evaluate prevalence and clinical and radiological characteristics of HPP in adults with T1D and (b) to review literature on the use of electronic medical records (EMR) for HPP case findings.
Recent findings: In our pilot study, 18 individuals had persistent low alkaline phosphatase levels (ALP) [18/1723, 1.05%]. Among 10 participants who completed the study with potential HPP and T1D, three had a pathogenic ALPL mutation (0.16% prevalence), and six had elevated serum vitamin B6. No significant differences were found in DXA-based bone density, QCT-based bone density, or Finite element-estimated bone strength between the potential HPP group, T1D adults, and controls. We did not find any study that evaluated persistent low ALP levels or potential HPP in patients with diabetes (either type 1 or type 2 diabetes). The literature reported higher prevalence of low ALP levels when electronic medical records were searched (~ 1-3%). However, prevalence of suspected HPP based on persistent low ALP levels and/or clinical signs and symptoms was around 0.5% or lower depending on sample size, methods and geographical locations. Our study suggests that EMR-based screening for HPP is feasible and may identify previously undiagnosed cases of HPP. Prevalence of potential HPP in T1D is around 1% and genetically confirmed HPP is 0.16% which is similar to reported prevalence of HPP in selected population without diabetes. Skeletal imaging and clinical presentations are not sufficient for identifying potential HPP in individuals with T1D. Given the increased fracture risk and low bone turnover typically seen in T1D, we propose that an EMR-based screening strategy could be a more effective approach for diagnosing HPP in T1D population.
期刊介绍:
This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of osteoporosis.
We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and future therapeutics, epidemiology and pathophysiology, and evaluation and management. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.